Esophageal Adenocarcinoma Methods and Protocols

22

Table 1(continued) Author

Experimental arm

Control arm

Outcomes

% of esophageal/esophagogastric junction adenocarcinoma

Subgroup outcomes

PostoperativeINT 0116 (2001,

2012) [

19

,^20

]

Postop

chemoRT

Surgery

alone

Improved OS (HR 1.32,

p^ =

0.0046) and RFS (HR

1.51,

p^

<^

0.001) at 10

years

~20%

Not reported

ACTS GC (2008,

2011) [

21

,^22

]

Postop S-1

Surgery

alone

Improved OS (HR 0.669) and

RFS (HR 0.653)

Not reported

Not reported

CLASSIC (2012,

2014) [

23

,^24

]

Postop

XELOX

Surgery

alone

Improved DFS (HR 0.58,

p^ <

0.0001) and OS (HR 0.66,

p^ =

0.0015)

2–3%

Not reported

Abbreviations:

PF

cisplatin and 5FU,

OS

overall survival,

PFS

progression-free survival,

mOS

median overall survival,

DFS

disease-free survival,

postop

postoperative,

RFS

relapse-

free survival,

XELOX

capecitabine and oxaliplatin

Ka-On Lam and Dora L. W. Kwong